Compare PROK & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROK | BNR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 252.7M |
| IPO Year | 2021 | 2019 |
| Metric | PROK | BNR |
|---|---|---|
| Price | $1.93 | $20.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 29.1K |
| Earning Date | 05-11-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.54 | $2.18 |
| 52 Week High | $7.13 | $41.72 |
| Indicator | PROK | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 60.27 |
| Support Level | $1.71 | $19.72 |
| Resistance Level | $2.58 | $23.42 |
| Average True Range (ATR) | 0.14 | 1.46 |
| MACD | 0.03 | 0.91 |
| Stochastic Oscillator | 78.95 | 99.84 |
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.